{"product_id":"zbh-bcg-matrix","title":"(ZBH) Zimmer Biomet Holdings, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Zimmer Biomet Holdings, Inc. BCG Matrix is a ready-made strategic analysis that helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs. It is used for portfolio review, strategy, and capital allocation, and this page already shows a real preview of the actual report content. Buy the full version to unlock the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eROSA Robotics platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eROSA Robotics is Zimmer Biomet Holdings, Inc.'s clearest growth engine, with robot-assisted knee and hip workflows still expanding through 2025. The company kept investing in software, data, and surgeon training to drive adoption, which fits a Star in the BCG Matrix. That matters because Zimmer Biomet posted about $8 billion in 2025 sales, and ROSA helps lift share in high-value ortho cases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCementless knee systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCementless knee systems fit the premium end of Zimmer Biomet Holdings, Inc.'s knee portfolio, where longer implant life and surgeon demand support pricing power. Zimmer Biomet reported 2024 net sales of about $7.7 billion, and this category can help sustain mix and margin. Continued clinical and commercial spend should help protect share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCementless hip systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCementless hip systems fit Zimmer Biomet Holdings, Inc.’s Star profile: hip reconstruction is a large global market, and premium, cementless designs are the faster-growing end of it. Zimmer Biomet Holdings, Inc. reported about $7.7 billion in 2025 net sales, and continued product refreshes support share gains in a high-value category. If adoption stays strong in 2026, this line can keep growing faster than the core market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSports medicine and biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSports medicine and biologics is a Star for Zimmer Biomet Holdings, Inc. because outpatient care keeps expanding and younger, active patients keep fueling arthroscopy demand. In 2025, the company still needed strong marketing and surgeon training to defend share in a crowded market, even as procedure volumes kept rising.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOutpatient care supports higher volume.\u003c\/li\u003e\n\u003cli\u003eArthroscopy demand keeps rising.\u003c\/li\u003e\n\u003cli\u003eShare defense needs training spend.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat mix fits a high-growth, high-share BCG Star, but it also means Zimmer Biomet must keep investing to hold its position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFoot and ankle, extremities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFoot and ankle, extremities fits Star status: elective extremity procedures are among the faster-growing orthopedic niches, and Zimmer Biomet Holdings, Inc. has a broad set across foot, ankle, and upper extremity implants. The category still has room for more surgeon adoption, so share gains can compound as procedure volumes rise. High growth plus improving penetration supports a Star view.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast-growing elective ortho segment\u003c\/li\u003e\n\u003cli\u003eBroad Zimmer Biomet Holdings, Inc. portfolio\u003c\/li\u003e\n\u003cli\u003eStill room to expand surgeon adoption\u003c\/li\u003e\n\u003cli\u003eShare gains can lift growth further\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimmer Biomet’s Growth Stars Power 2026 Share Gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimmer Biomet Holdings, Inc.'s Stars are ROSA Robotics, cementless knee and hip systems, sports medicine and biologics, and foot and ankle\/extremities. These are the faster-growing, higher-investment lines behind the Company's about $8 billion 2025 sales base. ROSA and premium implants still need heavy training and launch spend, but they can drive share gains in 2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eROSA\u003c\/td\u003e\n\u003ctd\u003eRobot workflow growth\u003c\/td\u003e\n\u003ctd\u003eCore growth engine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCementless\u003c\/td\u003e\n\u003ctd\u003ePremium mix, pricing power\u003c\/td\u003e\n\u003ctd\u003eShare gain focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eZimmer Biomet’s BCG Matrix maps its portfolio by growth and share to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClean BCG Matrix view for Zimmer Biomet Holdings, Inc., simplifying portfolio decisions and executive review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Zimmer Biomet Holdings, Inc., helping teams verify key claims and make faster, better-informed decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrimary total knee reconstruction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrimary total knee reconstruction is a mature cash cow for Zimmer Biomet Holdings, Inc., built on a large installed base and steady revision demand. In Zimmer Biomet Holdings, Inc.'s 2025 results, net sales were about $7.7 billion, showing the core orthopedics base still generates strong cash even with modest growth. Support spending is lower than in newer lines, so margin pressure stays limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrimary total hip reconstruction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimmer Biomet’s primary total hip reconstruction sits in a mature, high-volume market, with steady demand from a wide base of hospitals and surgeons. In FY2024, Zimmer Biomet posted $7.7 billion in net sales, and hip implants remain a core cash engine with lower reinvestment needs than growth niches. That makes it a classic Cash Cow: stable volume, repeat procedures, and reliable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevision reconstruction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevision reconstruction is a Cash Cow for Zimmer Biomet Holdings, Inc. because worn or failed hip and knee implants create repeat demand, and revisions already make up about 10% to 15% of total arthroplasty volume in mature markets. The segment grows slower than robotics or extremities, but it supports attractive margins and steady cash flow. Zimmer Biomet’s 2025 net sales were about $7.7 billion, and this recurring base helps fund faster-growth units.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBone cements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBone cements are a steady consumable for Zimmer Biomet Holdings, Inc., tied to the company’s joint-replacement base, which generated about $7.7 billion in latest annual net sales. Growth is modest, but repeat use in revision and primary arthroplasty keeps cash flow dependable, so this business fits the low-growth, high-share \"cash cow\" profile well.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring use drives stable cash flow\u003c\/li\u003e\n\u003cli\u003eDemand follows joint-replacement volume\u003c\/li\u003e\n\u003cli\u003eLow growth, strong share profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInstrumentation and disposables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZimmer Biomet's instrumentation and disposables are a Cash Cow because surgical trays, instruments, and support items are bought again and again with each procedure, not on a one-time cycle. With annual sales around $7.7 billion, the segment turns steady orthopedic procedure volume into repeat revenue and dependable cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat sales track procedure counts\u003c\/li\u003e\n\u003cli\u003eLow growth, high cash conversion\u003c\/li\u003e\n\u003cli\u003eSupports stable company margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis makes the line less dependent on big market expansion and more on installed surgeon use, so it behaves like a mature, reliable profit engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimmer Biomet’s Cash Cows Keep Revenue Steady\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimmer Biomet Holdings, Inc.'s Cash Cows are its mature knee, hip, revision, cement, and instrument lines, which turn recurring procedure volume into steady cash. In FY2025, net sales were about $7.7 billion, and these low-growth franchises still fund the business. The installed base keeps demand repeatable and margins durable.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow area\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eFY2025 anchor\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKnee and hip\u003c\/td\u003e\n\u003ctd\u003eHigh volume, repeat use\u003c\/td\u003e\n\u003ctd\u003eAbout $7.7 billion net sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevision and cements\u003c\/td\u003e\n\u003ctd\u003eRecurring demand\u003c\/td\u003e\n\u003ctd\u003eStable procedure-linked cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eZimmer Biomet Holdings, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Zimmer Biomet Holdings, Inc. BCG Matrix report you’ll receive after purchase. The full document is the same polished, ready-to-use file—no hidden changes, no demo content. Download it instantly and use it for analysis, presentations, or strategy planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy spine portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimmer Biomet Holdings, Inc. reported about $7.7 billion in 2025 net sales, but its legacy spine portfolio stayed a small, pressured part of Orthopedics. Spine is more crowded and less strategic than knee and hip, and Zimmer Biomet’s share is too modest to drive strong growth. That fits a low-share, low-attractiveness Dogs profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCraniomaxillofacial reconstruction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCraniomaxillofacial reconstruction is a niche slice of the musculoskeletal market, and Zimmer Biomet does not have the same scale here as in knee and hip reconstruction. Demand exists, but the segment is smaller, slower growing, and more fragmented, so it fits the Dog box in a BCG view. Limited share and weaker growth mean it likely ties up focus without giving back much cash.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThoracic fixation and sternal closure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThoracic fixation and sternal closure is clinically important, but for Zimmer Biomet Holdings, Inc. it remains a niche line inside a 2025 revenue base of about $8 billion. The market is mature, with low growth and limited scale, so it does not have the size or momentum of a Star. It also lacks the steady cash generation and share leadership needed for Cow status, so it fits Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneral surgical instruments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeneral surgical instruments sit in the Dogs box for Zimmer Biomet Holdings, Inc. because they are low-margin, close to commodity products, and face broad competition from many suppliers. The segment also has weak pricing power and limited differentiation, so growth and share stay thin even as Zimmer Biomet generated about $7.7 billion in FY2025 net sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow margin, high price pressure\u003c\/li\u003e\n\u003cli\u003eBroad competition, little differentiation\u003c\/li\u003e\n\u003cli\u003eWeak growth and weak share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-volume legacy accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLow-volume legacy accessories fit a Dogs profile: they can sit in inventory, field service, and sales coverage, but add little growth. Zimmer Biomet’s 2025 net sales were about $7.7 billion, so these old lines are small versus the core joint and spine franchises. They often stay only to support installed accounts and protect service ties, not to drive strategic leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, low share\u003c\/li\u003e\n\u003cli\u003eSupports installed base\u003c\/li\u003e\n\u003cli\u003eDrags inventory and service effort\u003c\/li\u003e\n\u003cli\u003eBest for harvest or rationalize\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimmer Biomet’s Legacy Lines Remain Small, Pressured Dogs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimmer Biomet Holdings, Inc. Dogs are mostly legacy, low-share lines like spine, cranio-maxillofacial, thoracic fixation, and general surgical tools. In FY2025, Zimmer Biomet Holdings, Inc. generated about $7.7 billion in net sales, but these units stayed small, mature, and pressured by weak growth and heavy competition. They add support value, yet they mostly consume capital and attention.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eBCG signal\u003c\/th\u003e\n\u003cth\u003eFY2025 note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy spine\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eSmall, pressured\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMF\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eNiche, fragmented\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThoracic fixation\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eMature, low growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral surgical tools\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eLow margin, commoditized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUpper extremity implants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUpper extremity implants fit Zimmer Biomet Holdings, Inc. as a Question Mark: shoulder and elbow demand is rising with the 62 million U.S. adults age 65+ and more outpatient surgery, but the category is still far smaller than knees and hips. Zimmer Biomet has a real presence here, yet it is not a dominant franchise. It likely needs more R\u0026amp;D and commercial spend to become a winner.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrauma fixation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimmer Biomet Holdings, Inc.'s trauma fixation sits in a market lifted by aging: the UN says people aged 65+ will reach about 1 in 6 globally by 2050, and more fractures mean more repair demand. In a crowded field with Stryker, Johnson \u0026amp; Johnson, and Smith+Nephew, share is harder to win than demand, so it fits a Question Mark. Zimmer Biomet Holdings, Inc. reported about $7.7 billion in 2025 net sales, but trauma still needs heavy share gains to turn into a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegenerative biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegenerative biologics fits the Question Mark box for Zimmer Biomet Holdings, Inc.: the orthopedic and sports medicine biologics market is growing fast, but Zimmer Biomet still has limited penetration versus larger rivals. The category can add meaningful value if adoption rises, yet it remains competitive and execution-heavy. Recent 2025 company reporting shows the business still needs stronger share gains to turn this exposure into a true growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital planning and analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital planning and analytics sit in a Question Mark spot for Zimmer Biomet Holdings, Inc.: surgery workflows are moving digital fast, and the company can use that pull to support implants and robotics, but standalone scale is still small. In 2025, Zimmer Biomet did not break out separate digital revenue, so share remains hard to measure. Heavy R\u0026amp;D and workflow integration could lift this into a Star if adoption keeps rising.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast workflow adoption supports cross-sell.\u003c\/li\u003e\n\u003cli\u003eStandalone share is still underbuilt.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D can drive Star conversion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRobotic hip expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRobotic hip expansion is a high-upside Question Mark for Zimmer Biomet Holdings, Inc. Robotics is still knee-led, but hip workflows are growing and could widen the installed base if adoption keeps rising. In 2024, Zimmer Biomet Holdings, Inc. reported about $7.7 billion in net sales, so even small hip-robot gains can matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth, low share today\u003c\/li\u003e\n\u003cli\u003eHip adoption is still building\u003c\/li\u003e\n\u003cli\u003eUpside depends on surgeon conversion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe key risk is that market share is not locked in yet, so rivals can still win accounts. If hip robotics scales faster in 2025, this could move from Question Mark toward a stronger growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimmer Biomet’s growth bets need proof, not just spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks in Zimmer Biomet Holdings, Inc. are upper extremity, trauma, biologics, digital planning, and hip robotics: each has growth, but none has clear share leadership. In 2025, Zimmer Biomet Holdings, Inc. reported about $7.7 billion net sales, so these bets need conversion, not just spend. If adoption and surgeon pull rise, they can move toward Stars.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpper extremity\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eGrowing with 62M U.S. 65+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrauma\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003e2025 sales base $7.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191836451081,"sku":"zbh-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/zbh-bcg-matrix.webp?v=1783678655","url":"https:\/\/dcfanalyst.com\/products\/zbh-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}